OncLive® On Air

By OncLive® On AirScience Health & Fitness

Favorites
21
Followers
Typical duration
19 min
per episode

Based on Podcast App listening data

OncLive® On Air episodes

January 20 S15 Ep31: Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium
In this podcast, experts Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD, discuss frontline, second-line, and antibody-drug conjugate therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.
32 min
January 20 S15 Ep30: Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms
In this podcast, experts Tiffany A. Traina, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, Mark E. Robson, MD, FASCO, and Rebecca Shatsky, MD discuss data for CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors in the management of early-stage hormone receptor-positive, HER-2-negative breast cancer.
30 min
January 20 S15 Ep29: Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy
In this podcast, experts Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; and Neeta Pandit-Taskar, MD, MBA, discuss the latest evidence on PSMA PET and RLT, including combination strategies, selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.
28 min
January 16 S15 Ep28: Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
In today’s episode, we had the pleasure of speaking with Rahul Banerjee, MD, FACP, about the ongoing investigation of CELMoDs for multiple myeloma. Dr Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center, as well as an assistant professor in the Division of Hematology and Oncology at the University of Washington in Seattle.
In our exclusive interview, Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with traditional immunomodulatory drugs (IMiDs) like lenalidomide (Revlimid) and pomalidomide (Pomalyst). He also noted strong preclinical and clinical data with CELMoDs, as well as their favorable safety profiles that include fewer immune and hematopoietic effects. Additionally, he explained that early data suggest that CELMoDs could replace traditional IMiDs, offering better long-term outcomes and fewer adverse effects.
19 min
January 16 S15 Ep27: Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life
In this podcast, experts Sara A. Hurvitz, MD, FACP, Michelle Melisko, MD, and Paolo Tarantino, MD, PhD, discuss approaches to maintenance and subsequent lines of therapy for patients with HER2+ advanced breast cancer, including those with CNS metastases.
22 min
January 15 S15 Ep26: FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD
In today’s episode, the discussion features Lorenzo Falchi, MD, a medical oncologist/hematologist and assistant attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, who provided clinical and regulatory perspectives on the FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan) and lenalidomide (Revlimid) for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy. The approval was supported by primary results from the randomized phase 3 EPCORE FL-1 trial (NCT05409066).
In this exclusive interview, Dr Falchi discussed why this approval is clinically meaningful—establishing a chemotherapy-free triplet that significantly improves outcomes over the long-standing rituximab/lenalidomide backbone in the second-line setting and beyond—and reviewed practical considerations that inform real-world uptake of the regimen, including outpatient administration feasibility and mitigation of bispecific antibody–associated toxicities, such as cytokine release syndrome. He also placed EPCORE FL-1 in the broader epcoritamab development program, referencing supportive experience with the phase 1/2 EPCORE NHL-2 trial (NCT04663347) and ongoing efforts to move bispecific antibody–based regimens earlier in the treatment paradigm through the phase 3 EPCORE FL-2 trial (NCT06191744).
any of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
18 min
January 09 S15 Ep25: FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD
In today’s episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).
10 min
January 07 S15 Ep24: PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD
In today’s episode, the discussion features Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), drawing on efficacy and safety findings from the phase 3 COMPETE trial (NCT03049189).
9 min
January 05 S15 Ep23: Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO
In this episode of Precision and Progress: Radiotherapy in Oncology, Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, co-hosted a discussion with Valentina Bonev, MD, DABS, FACS, FSSO, about the interplay between surgery and radiation in breast cancer care.
27 min
December 31, 2025 S15 Ep22: CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD
In today’s episode, the discussion features Joanna M. Rhodes, MD, MSCE, director of Lymphoma and systems head for Lymphoma at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, alongside Krish Patel, MD, director of Lymphoma Research and executive chair of the Lymphoma Research Executive Committee at the Sarah Cannon Research Institute. Together, they discussed how the chronic lymphocytic leukemia (CLL) treatment paradigm continues to evolve with advances in targeted therapy.

In this exclusive interview, Drs Rhodes and Patel highlighted key disease- and patient-related factors that guide first-line treatment selection, considerations that influence sequencing decisions in later lines of therapy, and how hematologists determine the optimal timing to transition between treatments. They also discussed the clinical distinctions between covalent and noncovalent BTK inhibitors, the current role of pirtobrutinib (Jaypirca) in CLL management, and how its safety profile and emerging data may inform future use earlier in the treatment course. The conversation concluded with reflections on the CLL data presented at the 2025 ASH Annual Meeting that were most relevant to clinical practice.
nd many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
22 min

About OncLive® On Air

From the publisher's feed

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in…